In the short term, there are 3 events on the schedule in the next 12 days. ROTH, Alberta Epigenetics Network (also on Zenith's schedule) and Richmond Club.

Last year's Richmond Club presentation occurred during the exciting month of April 2015 that also featured announcments of the patents for RVX-208 in China and the Hepalink Licensing & Equity Arrangement. The March/April time period of 2015 saw the share price go from ~$1 to near $3.

Not that we should expect a repeat of the cycle exactly in 2016 compared to 2015, but many of those same catalysts from 2015 seem to be recurring: ROTH, Richmond, another licensing deal announcement (per DM's webcast). Plus we are hearing that planning of RVX-208 kidney dialysis trial and PNH trial are progressing. Based on the stellar job that Mike Sweeney and company did with the BETonMACE design and implementation, as well as the very convincing data showing how RVX-208 affects the complement pathway and alkaline phosphatase, announcments regarding these two trials would be well received (at least by me!) and could be a catalyst.

In the longer term, in about 7 weeks on April 28th is a very interesting Epigenetics meeting that has the potential to make a lot of noise. Also nearby that date is the Epigenetic Inhibitor Discovery meeting that Zenith is presenting at

I like to schedule my expectations of new announcements/catalysts around scheduled events, in which case the March 13-23rd range as well as the April 19-28th range are on my radar. Of course, no guarantees that anything happens in the next 7 weeks, but seems like if they had something big to announce soon that coinciding its announcement with one of these events makes sense.

BearDownAZ